FLT3 and acute myeloid leukemia: The more recent ELN2017 genetic risk stratification specified that this subgroup of AML patients with wild‐type NPM1 and no FLT3‐ITD (or with FLT3‐ITD low) was classified in the intermediate‐risk category if they did not have any adverse‐risk genetic lesion.